antibodi
structur
compris
pair
ident
heavi
light
chain
link
disulphid
bond
held
yshape
arrang
figur
fragment
antigenbind
fab
portion
region
bind
antigen
compos
one
variabl
one
constant
domain
heavi
light
chain
remain
constant
section
longer
heavi
chain
form
tail
term
crystalliz
fragment
fc
region
provid
signal
effector
function
antibodi
provid
protect
effect
variou
mechan
viral
neutral
gener
meant
abil
antibodi
provid
suffici
steric
interfer
disrupt
interact
microb
antigen
ligand
experiment
condit
vitro
activ
clearli
associ
protect
thank
fab
domain
alon
natur
infect
immun
viru
infect
includ
sequenti
step
begin
attach
cellsurfac
receptor
end
deliveri
viral
genet
materi
cytoplasm
fusion
viral
cellular
membran
basic
entri
mode
envelop
virus
hiv
hcv
still
differ
specif
aspect
viral
entri
assembl
thu
offer
uniqu
therapeut
opportun
cell
surfac
certainli
directli
access
action
antibodi
therefor
phase
viru
entri
one
import
target
prevent
viral
infect
origin
mani
known
nab
act
step
reason
inhibit
releas
progeni
viru
anoth
possibl
mechan
neutral
demonstr
antibodi
direct
influenza
virion
surfac
neuraminidas
hiv
hcv
field
viru
releas
inhibit
antibodi
identifi
date
interact
hiv
envelop
surfac
protein
host
receptor
human
cell
trigger
conform
chang
envelop
result
exposur
transient
bind
site
coreceptor
turn
promot
addit
conform
chang
viru
protein
allow
insert
fusion
peptid
target
cell
membran
initi
membran
fusion
viral
entri
host
cell
nab
inhibit
viral
infect
sever
differ
mechan
parallel
step
allow
virus
enter
cell
figur
directli
block
viru
attach
target
cell
interf
virusreceptor
interact
case
nab
site
hiv
goal
also
achiev
direct
antibodi
viru
receptor
andor
coreceptor
host
cell
mab
also
block
fusion
cell
membran
postbindingprefus
stage
exemplifi
andor
ccmotif
receptor
receptor
mab
develop
mab
direct
extern
proxim
membran
region
hiv
interfer
conform
chang
need
membran
fusion
unlik
hiv
hcv
entri
target
cell
occur
via
clathrinmedi
endocytosi
viral
particl
subsequ
releas
viral
genom
cytosol
requir
phdepend
fusion
viral
cellular
membran
current
model
suggest
hcv
circul
lipoviralparticl
lvp
vascular
system
consist
lipoprotein
complex
viru
particl
follow
local
surfac
hepatocyt
interact
lvp
glycosaminoglycan
low
densiti
lipoprotein
receptor
specif
bind
viru
surfac
glycoprotein
host
scaveng
receptor
occur
subsequ
viral
particl
transloc
region
membran
possess
tight
junction
protein
occludin
claudin
bind
receptor
result
clathrinmedi
endocytosi
hiv
mab
direct
spike
viral
protein
well
host
receptor
may
act
earli
stage
infect
prevent
bind
viru
cell
surfac
exampl
antibodi
recogn
site
within
envelop
glycoprotein
shown
block
viral
entri
number
antireceptor
antibodi
target
srbi
antibodi
may
act
block
conform
chang
andor
requisit
interact
viral
endosom
membran
requir
fusion
although
yet
fusion
determin
within
envelop
glycoprotein
defin
host
protect
vivo
complex
involv
interact
antibodi
cell
molecul
innat
immun
system
antibodi
exert
protect
action
fc
regionmedi
recruit
compon
immun
system
includ
antibodydepend
cellmedi
cytotox
adcc
complementdepend
cytotox
cdc
antibodydepend
cellular
phagocytosi
receptor
fc
segment
igg
fci
receptor
express
surfac
differ
type
cell
includ
natur
killer
cell
nk
monocyt
macrophag
dendrit
cell
neutrophil
except
cell
normal
found
lymphocyt
similarli
receptor
fc
segment
iga
involv
phagocytosi
induct
microb
kill
express
monocyt
macrophag
neutrophil
adcc
process
trigger
interact
fc
region
antibodi
bound
nonself
antigen
expos
host
cell
fc
receptor
immun
effector
cell
subsequ
releas
cytokin
cytotox
granul
contain
perforin
granzym
promot
death
target
cell
cdc
initi
complement
compon
bind
fc
region
igg
turn
bound
foreign
antigen
cell
surfac
trigger
proteolyt
cascad
activ
complement
lead
format
membran
attack
complex
kill
target
cell
disrupt
cell
membran
fc
region
also
mediat
complement
bind
deposit
free
virion
caus
direct
virotox
effect
inhibit
viru
bind
cell
moreov
socal
opson
process
consist
bind
antibodi
fab
portion
antigen
follow
interact
fc
domain
fc
receptor
phagocyt
power
mechan
enhanc
phagocytosi
respect
hiv
potenti
role
adcc
modul
cours
hiv
infect
first
propos
basi
studi
show
invers
associ
adcc
antibodi
level
clinic
stage
diseas
strongest
evid
role
adcc
antibodi
diseas
progress
come
studi
baum
et
al
multicent
aid
cohort
studi
studi
rapid
progressor
significantli
lower
adcc
antibodi
titer
cem
nkr
cell
coat
nonrapid
progressor
correspond
visit
nonprogressor
visit
morev
hivinfect
individu
spontan
undetect
viremia
shown
higher
adcc
antibodi
level
virem
subject
context
hcv
infect
fcmediat
effector
function
although
less
well
understood
still
import
role
sera
acut
chronic
phase
infect
mediat
adcc
via
bind
viral
protein
express
cell
surfac
sever
mab
abl
induc
cdc
cell
optim
nonnab
effector
function
adcc
cdc
fagogocytosi
may
prove
critic
design
new
effect
antihcv
therapeut
antibodi
mani
virus
includ
hiv
hcv
develop
mechan
evas
andor
modif
host
innat
adapt
immun
respons
often
caus
persist
viral
infect
one
extens
investig
exampl
evas
host
adapt
immun
system
exhaust
virusspecif
cell
exhaust
consist
progress
dysfunct
character
inabl
prolifer
produc
key
antivir
immun
stimul
cytokin
exampl
interleukin
il
tumor
necrosi
factor
tnf
interferon
ifn
lyse
infect
cell
featur
function
exhaust
affect
mani
antivir
properti
mous
human
cell
loss
effector
function
proce
hierarch
manner
start
defect
product
prolifer
follow
decreas
tnf
product
cytotox
activ
also
lack
exhaust
human
cell
sever
stage
exhaust
product
eventu
compromis
exhaust
cell
end
delet
high
antigen
load
persist
exhaust
also
occur
cell
mice
human
probabl
best
explan
progress
dysfunct
loss
effector
cell
continu
trigger
virusspecif
cell
receptor
owe
high
antigen
load
persist
infect
host
without
critic
rest
period
current
consensu
function
exhaust
way
limit
magnitud
effector
cell
respons
although
may
safeguard
autoimmun
respons
may
also
compromis
effect
immun
persist
infecti
agent
tumor
exhaust
cell
subject
complex
layer
neg
regul
involv
signal
multipl
inhibitori
receptor
inhibit
function
prolif
respons
famili
member
program
cell
death
shown
highli
express
inhibitori
receptor
cell
chronic
infect
major
role
regul
cell
exhaust
infect
increas
express
cell
also
occur
hbv
hcv
infect
sever
inhibitori
receptor
also
shown
induc
cell
unrespons
chronic
infect
receptor
includ
cytotox
lymphocyt
antigen
cell
immunoglobulin
domain
mucin
domain
protein
lymphocyt
activ
gene
addit
certain
cytokin
transform
growth
well
regulatori
cell
may
also
contribut
lack
cell
function
situat
high
antigen
burden
intrigu
evid
blockad
inhibitori
receptor
could
restor
antigen
cell
respons
exampl
blockad
signal
pathway
improv
antigenspecif
cell
prolifer
cytokin
secret
lymphocyt
choriomening
viru
lcmv
infect
mice
human
chronic
hiv
hbv
hcv
infect
effect
synergist
improv
lcmv
infect
mous
follow
simultan
blockad
cell
inhibitori
receptor
thank
diminish
viral
load
vivo
observ
although
block
pathway
alon
littl
effect
sever
exhaust
moreov
mabmedi
block
pathway
vitro
augment
hivspecif
tcell
function
suggest
immun
modul
target
may
also
provid
clinic
benefit
infect
individu
anoth
exampl
manipul
signal
mediat
glucocorticoidinduc
tnf
receptor
gitr
recent
identifi
member
tnf
receptor
superfamili
preferenti
express
subset
regulatori
cell
gitr
signal
break
suppress
activ
subset
fact
agonist
antigitr
mab
immedi
inject
viral
infect
significantli
increas
number
activ
cell
secret
one
must
rememb
manipul
immunolog
respons
could
detriment
effect
host
highlight
recent
tragic
human
trial
mab
human
cell
costimulatori
molecul
develop
tegenero
treat
bcell
chronic
lymphocyt
leukaemia
autoimmun
inflammatori
diseas
basi
capabl
induc
preferenti
activ
expans
immunosuppress
regulatori
treg
cell
observ
rodent
model
term
superagonist
bind
activ
cell
without
need
prior
cell
antigen
receptor
tcr
signal
phase
clinic
trial
march
follow
administr
six
healthi
young
men
suffer
lifethreaten
cytokinereleas
syndrom
cr
involv
multiorgan
failur
someth
unpredict
preclin
studi
clear
presenc
activ
effector
memori
tem
cell
sourc
cytokin
mediat
cr
observ
volunt
treg
cell
abl
prevent
system
inflamm
probabl
balanc
activ
treg
cell
tem
cell
number
disadvantag
human
compar
laboratori
rodent
furthermor
macaqu
human
cell
lose
express
differenti
tem
cell
detail
howev
gone
unnot
despit
mani
year
primat
test
conclus
model
fail
prevent
disastr
case
view
event
risk
need
care
assess
modul
immun
inhibitori
activ
receptor
use
increas
function
activ
virusspecif
cell
order
avoid
nonspecif
inflamm
therapeut
approach
care
evalu
cancer
well
hiv
hcv
chronic
viral
diseas
given
potenti
antivir
effect
antibodi
virus
evolv
multipl
mechan
protect
antibodi
bind
one
viral
receptor
glycosyl
wide
share
among
differ
virus
carbohydr
poorli
immunogen
therefor
stimul
respons
type
b
lymphocyt
simultan
hide
underli
protein
structur
hcv
protein
contain
potenti
nlink
glycosyl
site
specif
glycan
mask
site
therefor
nab
epitop
lipid
shield
may
repres
addit
strategi
use
hcv
evad
antibodi
respons
current
data
suggest
key
neutral
epitop
less
access
lvp
recent
hcv
found
capabl
direct
celltocel
transmiss
larg
resist
antibodi
neutral
hiv
envelop
protein
also
glycosil
chang
occur
frequenc
posit
glycan
hiv
evolv
glycan
shield
shown
decreas
sensit
antibodi
neutral
factor
antibodi
escap
hiv
trimer
gp
gp
shield
vulner
epitop
better
expos
individu
monomer
subunit
kinet
spatial
constraint
imped
antibodi
access
potenti
vulner
site
receptor
bind
membran
fusion
process
variabl
loop
prime
target
nab
usual
narrow
breadth
reactiv
final
high
mutat
rate
mani
virus
includ
hiv
hcv
undergo
rapid
antigen
variat
allow
escap
neutral
constitut
signific
hurdl
nab
develop
problem
may
counterbalanc
select
nab
target
conserv
access
area
viral
particl
andor
use
mixtur
nab
target
variou
key
epitop
fact
demonstr
combin
therapi
mab
cocktail
prevent
escap
variant
mani
virus
includ
influenza
coronaviru
lcmv
broad
neutral
sera
individu
hiv
infect
donor
associ
singl
four
five
princip
specif
recent
studi
indic
nab
play
critic
role
hcv
diseas
outcom
viral
clearanc
associ
rapid
induct
neutral
antibodi
earli
phase
infect
evid
antibodi
broadli
reactiv
contrast
chronic
hcv
infect
character
absent
lowtit
neutral
antibodi
earli
phase
infect
persist
infect
despit
induct
crossneutr
antibodi
later
phase
infect
current
understand
nab
respons
rais
hcv
suggest
major
target
multipl
epitop
within
may
target
linearand
conformationdepend
antibodi
predominantli
neutral
epitop
overlap
site
clearli
demonstr
role
inhibit
entri
current
one
mab
investig
clinic
trial
prevent
liver
reinfect
transplant
novel
antivir
prevent
therapeut
strategi
urgent
need
fact
reinfect
graft
univers
character
acceler
progress
liver
diseas
ifnbas
therapi
exhibit
enhanc
advers
effect
limit
efficaci
patient
fulli
human
monoclon
antibodi
isol
transgen
mice
direct
highli
conserv
linear
epitop
hcv
glycoprotein
abl
neutral
pseudovirus
multipl
hcv
genotyp
demonstr
efficaci
prevent
hcv
infect
hcv
chimpanze
phase
openlabel
dose
escal
studi
perform
healthi
adult
volunt
start
mgkg
escal
mgkg
postinfus
safeti
review
welltoler
without
serious
advers
effect
event
base
favor
safeti
toler
pharmacokinet
data
phase
ii
studi
chronic
infect
hcv
patient
undergo
liver
transplant
plan
context
hiv
diseas
despit
intens
studi
two
decad
small
number
broadli
neutral
mab
identifi
infect
patient
littl
known
activ
vivo
antibodi
abl
inhibit
viral
entri
primari
hiv
isol
vitro
except
high
level
mutat
found
gene
may
reflect
chronic
immun
respons
hiv
persist
hypermut
select
number
trial
evalu
differ
formul
antihiv
monoclon
antibodi
progress
first
trial
assess
chimer
monoclon
antibodi
cgp
loop
envelop
week
subsequ
studi
evalu
kinet
monoclon
antibodi
direct
site
human
antibodi
bind
epitop
gpgraf
final
human
mab
evalu
clinic
trial
epitop
map
aa
igpgra
tip
loop
envelop
protein
demonstr
crossneutr
activ
isol
clade
b
drug
base
mab
cocktail
mode
also
current
clinic
develop
regard
alreadi
observ
hiv
neutral
assay
effect
mix
broadli
neutral
antibodi
increas
synergist
compar
effect
individu
antibodi
synergi
effect
rel
weak
maximum
two
fourfold
enhanc
antibodi
pair
therebi
increas
neutral
titer
tripl
quadrupl
antibodi
combin
howev
use
antibodi
cocktail
mode
approach
improv
effect
alreadi
recogn
pathogen
toxin
case
tetanu
toxin
report
combin
action
three
four
antibodi
increas
neutral
activ
time
case
botulinum
toxin
neutral
activ
report
time
higher
use
mixtur
three
monoclon
antibodi
instead
studi
demonstr
combin
two
potent
neutral
mab
hiv
although
synergist
mediat
addit
neutral
viral
activ
provid
improv
neutral
coverag
viral
strain
combin
independ
epitop
target
proofofconcept
passiv
immun
trial
human
demonstr
cocktail
three
broadli
neutral
mab
abl
delay
viral
rebound
patient
whose
infect
fulli
suppress
antiretrovir
treatment
administr
antibodi
interestingli
main
antivir
effect
observ
primarili
attribut
antibodi
mab
bind
noncontinu
epitop
compos
glycosyl
residu
distribut
envelop
protein
wherea
two
mab
recogn
two
adjac
highli
conserv
epitop
membraneproxim
ectodomain
envelop
protein
earlier
phase
clinic
trial
safeti
toler
demonstr
longterm
multipl
dose
phase
ii
clinic
trial
high
dose
three
neutral
antibodi
given
combin
individu
weekli
interv
three
month
pharmacokinet
analysi
reveal
repeat
infus
high
dose
level
well
toler
patient
elicit
endogen
immun
respons
monoclon
antibodi
antibodi
show
distribut
elimin
kinet
similar
seen
humanlik
antibodi
though
monoclon
antibodi
significantli
longer
elimin
halflif
day
monoclon
antibodi
day
day
furthermor
analys
emerg
mutat
confer
resist
three
mab
perform
sequenc
analysi
epitop
relev
nglycosyl
site
virus
deriv
patient
demonstr
mutat
site
associ
resist
vitro
select
experi
isol
four
individu
corrobor
vivo
find
viru
strain
rapidli
escap
pressur
importantli
vitro
select
demonstr
resist
nab
difficult
achiev
lead
select
variant
impair
infect
moreov
gener
virus
resist
triplecombin
slower
process
character
recurr
loss
viru
replic
gener
tripleresist
virus
seem
impair
replic
fit
none
patient
develop
detect
virus
escap
neutral
three
mab
within
observ
period
true
mab
design
infecti
diseas
develop
success
vaccin
would
reduc
need
howev
given
scarciti
drug
field
virolog
given
slow
progress
hiv
vaccin
front
develop
use
microbicid
compound
could
appli
topic
prevent
hiv
transmiss
one
possibl
strategi
counter
spread
hiv
regard
mab
could
propos
suitabl
compon
microbicid
fight
hiv
entri
mucos
surfac
safeti
studi
mab
administ
vagin
healthi
women
complet
broadli
neutral
mab
manufactur
tobacco
plant
mab
clinic
trial
produc
use
system
call
chines
hamster
ovari
cell
chocel
ferment
includ
use
along
antibodi
cocktail
chocel
ferment
product
method
expens
produc
enough
mab
scale
requir
global
market
therefor
plant
manufactur
mab
may
hope
offer
solut
lower
product
cost
improv
output
process
yield
five
gram
purifi
antibodi
kg
tobacco
product
cost
could
time
lower
use
convent
bioreactor
studi
design
confirm
safeti
vagin
deliv
mab
deriv
plant
manufactur
good
manufactur
practic
qualiti
standard
use
manufactur
medicin
product
medicin
first
plantproduc
antibodi
greenlit
clinic
test
britain
medicin
healthcar
product
agenc
mhra
took
year
get
agenc
stamp
approv
requir
assur
drug
contain
allergen
plant
sugar
pesticid
matter
produc
antibodi
shown
actual
prevent
infect
clinic
trial
thu
version
made
tobacco
plant
would
see
approv
time
soon
would
also
like
one
ingredi
cocktail
plantproduc
antibodi
elimin
reduc
develop
escap
variant
propos
target
conserv
cellular
receptor
viru
may
open
new
avenu
viabl
antibodi
therapi
hiv
infect
hiv
entri
cell
requir
presenc
coreceptor
either
target
cell
thu
base
hypothesi
mab
direct
coreceptor
develop
analyz
clinic
trial
function
coreceptor
physic
associ
tcr
ag
recognit
bind
nonpolymorph
compon
major
histocompat
complex
mhc
class
ii
molecul
surfac
antigenpres
cell
ibalizumab
human
mab
bind
cell
surfac
away
bind
site
mhc
class
ii
molecul
inhibit
bind
appear
exert
antivir
properti
postbind
conform
effect
prevent
interact
contrast
monoclon
antibodi
competit
inhibit
bind
interfer
mhc
class
ii
immun
function
report
human
experi
ibalizumab
consist
three
clinic
trial
phase
studi
observ
peak
mean
reduct
viral
load
occur
later
higher
dose
cohort
wherea
extent
durat
viral
suppress
correl
degre
cell
coat
ibalizumab
maintain
longer
higher
dose
cohort
durat
day
peak
increas
count
one
day
infus
well
peak
declin
viral
load
suggest
increas
may
due
redistribut
cell
lymphoid
tissu
rather
regener
cell
set
viral
suppress
multidos
studi
demonstr
continu
safeti
extend
treatment
period
provid
data
develop
ibalizumab
resist
resist
test
show
reduc
suscept
rel
baselin
resist
isol
remain
depend
viral
entri
suggest
resist
develop
use
altern
receptor
genotyp
analysi
unabl
identifi
mutat
diagnost
ibalizumab
resist
consist
alloster
mechan
ibalizumab
effect
develop
resist
associ
reduct
maximum
percentag
inhibit
rather
shift
characterist
competit
inhibitor
halflif
igg
normal
physiolog
circumst
two
three
week
contrast
averag
halflif
ibalizumab
day
consist
observ
antibodi
intern
shed
receptor
result
rapid
antibodi
degrad
random
doubleblind
placebo
control
phase
iia
studi
evalu
ibalizumab
efficaci
result
show
consider
viral
load
reduct
respect
placebo
arm
chemokin
receptor
mediat
activ
migrat
cell
leukocyt
virus
typic
mediat
transmiss
predomin
progress
symptomat
diseas
virus
use
altern
chemokin
receptor
either
exclus
addit
viru
present
initi
tend
result
increas
proport
subject
later
stage
diseas
coreceptor
antagonist
repres
emerg
antiretrovir
treatment
class
first
target
host
molecul
current
two
mab
investig
one
fulli
human
monoclon
antibodi
robust
activ
divers
panel
isol
synerg
vitro
arv
class
appear
safe
effect
reduc
hiv
viral
load
high
level
receptor
occup
observ
day
highest
dose
cohort
suggest
potenti
weekli
fortnightli
even
monthli
dose
mab
pro
human
mab
also
synerg
smallmolecul
antagonist
laboratori
studi
investig
two
mode
administr
classic
intraven
iv
form
subcutan
sc
form
trial
involv
sc
administr
first
bear
proof
concept
mab
administ
subcutan
infect
subject
potent
longact
antiretrovir
agent
iv
form
pro
test
monotherapi
subject
viru
detect
demonstr
potent
prolong
antivir
activ
mean
reduct
rna
safeti
rel
placebo
success
random
doubleblind
placebocontrol
iia
trial
examin
antivir
activ
toler
pharmacokinet
singl
intraven
infus
mab
pro
subject
treat
mgkg
experienc
reduct
rna
level
one
except
poststudi
analysi
use
enhancedsensit
trofil
assay
determin
subject
dualmix
viru
screen
chang
coreceptor
tropism
emerg
pro
viru
cours
studi
support
view
pro
broadli
inhibit
high
barrier
resist
maximum
toler
dose
iv
pro
determin
suggest
sizeabl
margin
safeti
pro
sc
administr
studi
studi
involv
pro
sc
administr
show
virolog
suppress
success
dose
chang
viral
suscept
pro
follow
three
week
monotherapi
indic
adapt
viru
use
presenc
drug
pharmacokinet
data
suggest
possibl
drug
regimen
administ
fortnightli
hiv
infect
individu
protein
macromolecul
drain
sc
site
blood
capillari
lymphat
system
anim
protein
molecular
weight
greater
dalton
observ
drain
primarili
lymphat
system
follow
sc
administr
protein
transit
lymph
fluid
typic
absorb
significantli
blood
reach
thorac
duct
sinc
molecular
weight
pro
approxim
dalton
substanti
amount
sc
pro
expect
drain
lymphat
system
potenti
encount
cell
lymphoid
tissu
prior
reach
bloodstream
reason
serum
concentr
may
provid
full
pictur
overal
exposur
follow
sc
dose
pro
sc
infus
current
use
individu
primari
immunodefici
selfadminist
home
significantli
larger
amount
approxim
gram
volum
approxim
ml
total
mlsite
weekli
scadminist
immunoglobulin
selfadministr
mg
sc
pro
would
much
simpler
comparison
therefor
sc
pro
offer
potenti
signific
dosedepend
rna
suppress
may
offer
greater
conveni
mani
patient
term
patient
selfadministr
sc
inject
mode
chosen
order
evalu
safeti
efficaci
adjunct
oral
antiretrovir
regimen
hivinfect
inject
drug
user
viral
rebound
document
poor
adher
previou
antiretrovir
regimen
therefor
phase
iib
nation
multicent
random
doubleblind
placebocontrol
studi
initi
current
recruit
particip
given
complic
aris
occurr
drug
resist
use
antibodi
togeth
combin
therapi
increas
drug
number
therefor
therapeut
opportun
particular
case
inhibitor
one
report
demonstr
resist
inhibitor
may
increas
sensit
resist
viru
certain
neutral
antibodi
compar
block
agent
therapi
hiv
less
attract
due
crucial
role
mani
biolog
process
absenc
date
known
natur
occur
mutat
lead
inactiv
gene
human
moreov
one
major
problem
link
fact
wherea
virus
found
patient
virus
use
coreceptor
usual
present
mix
togeth
virus
therefor
use
specif
mab
could
result
littl
transient
effect
overal
viremia
also
complic
evalu
pharmacolog
activ
howev
antibodi
might
still
provid
benefit
hiv
posit
patient
coadministr
antagonist
safeti
combin
establish
press
need
antivir
agent
effect
multipl
class
virus
broad
specif
might
achiev
target
phospholipid
wide
express
infect
host
cell
viral
envelop
phosphatidylserin
ps
abund
anion
phospholipid
plasma
membran
segreg
inner
leaflet
plasma
membran
rest
mammalian
cell
loss
ps
asymmetri
occur
apoptosi
cell
injuri
cell
activ
malign
transform
result
inhibit
translocas
activ
ps
export
lipid
scrambl
enzym
scramblas
envelop
virus
replic
within
host
cell
creat
envelop
carri
along
part
host
cell
membran
upon
exit
result
target
phospholipid
becom
expos
surfac
viru
well
infect
host
cell
bavituximab
first
new
class
patent
antibodi
therapeut
target
preferenti
bind
expos
phospholipid
demonstr
broad
therapeut
potenti
across
multipl
oncolog
indic
repres
new
approach
treat
viral
diseas
bavituximab
current
evalu
random
phase
ii
clinic
trial
nonsmal
cell
lung
cancer
pancreat
cancer
therapi
chronic
hcv
infect
hivhcv
coinfect
therapeut
effect
bavituximab
appear
due
adcc
tumor
virusinfect
cell
sinc
ps
exposur
earli
event
viru
infect
adcc
may
limit
viru
spread
furthermor
infecti
diseas
set
bavituximab
caus
opson
clearanc
infecti
viru
bloodstream
leav
less
viru
infect
tissu
three
complet
phase
hcv
clinic
trial
shown
bavituximab
gener
safe
welltoler
reduct
serum
hcv
rna
level
also
observ
random
phase
ii
clinic
trial
previous
untreat
hcv
infect
patient
design
determin
earli
virolog
respons
evr
rate
week
therapi
bavituximab
combin
antivir
drug
ribavirin
safeti
profil
versu
pegyl
ribavirin
result
show
combin
bavituximab
ribavirin
better
safeti
profil
ifncontain
regimen
howev
evr
develop
bavituximabcontain
arm
later
ifncontain
group
therefor
longerterm
evalu
need
adequ
compar
effect
addit
lower
dose
level
appear
activ
hcv
patient
high
dose
result
suggest
futur
studi
evalu
longer
bavituximab
treatment
durat
around
lower
dose
level
combin
ribavirin
potenti
direct
act
antivir
certain
patient
popul
may
hold
promis
ifnfre
hcv
therapeut
regimen
target
ps
cell
infect
multipl
differ
virus
virion
promis
antivir
strategi
although
resist
develop
monotherapi
trial
ibalizumab
antibodi
hostderiv
antigen
anion
phospholipid
virusinfect
cell
independ
viral
genom
consequ
acquisit
drug
resist
theoret
less
problemat
agent
target
virusencod
compon
sinc
discoveri
inhibitori
receptor
associ
tcell
dysfunct
role
variou
inhibitori
receptor
virusspecif
cell
extens
studi
human
chronic
viral
infect
hcv
hbv
hiv
infect
block
inhibitori
receptor
vitro
restor
function
virusspecif
cell
novel
hiv
hcv
treatment
base
blockad
sever
immun
checkpoint
molecul
investig
particular
mab
interf
two
major
inhibitori
network
famili
name
pathway
current
studi
clinic
trial
evalu
safeti
efficaci
mab
recogn
receptor
neutral
bind
respect
ligand
pathway
deliv
inhibitori
signal
regul
cell
activ
result
perform
key
role
variou
process
name
multipl
toler
checkpoint
prevent
autoimmun
suppress
tumor
microenviron
immunemedi
tissu
damag
host
defens
aim
erad
microbi
pathogen
tumor
final
cell
exhaust
contribut
lack
viral
control
chronic
infect
cell
unrespons
cancer
strong
correl
increas
express
tumor
neg
surviv
prognosi
patient
alreadi
observ
variou
studi
indic
mab
target
signal
pathway
reinvigor
antigenspecif
tcell
respons
promot
immun
respons
fight
tumor
hcv
infect
relationship
express
outcom
acut
hcv
infect
question
subsequ
recent
studi
shown
progress
acut
hcv
infect
chronic
stage
associ
high
level
hcvspecif
cell
wherea
clearanc
hcv
infect
associ
lower
level
express
given
premis
fulli
human
antibodi
also
known
human
antibodi
interact
receptor
develop
treatment
cancer
diseas
therapi
chronic
hcv
infect
date
clinic
experi
blockad
gain
tumor
set
drugrel
grade
toxic
effect
occur
patient
drugrel
advers
event
special
interest
potenti
immunerel
caus
includ
pneumon
vitiligo
coliti
hepat
hypophys
thyroid
pneumon
rang
isol
radiograph
abnorm
progress
diffus
infiltr
associ
clinic
symptom
small
number
patient
although
three
death
occur
mildtomoder
pneumon
manag
success
either
observ
glucocorticoid
howev
object
respons
observ
approxim
one
four
one
five
patient
nonsmallcel
lung
cancer
melanoma
renalcel
cancer
overal
adverseev
profil
appear
preclud
use
besid
studi
ongo
phase
safeti
trial
activ
hepat
c
genotyp
infect
patient
design
assess
safeti
toler
profil
clinic
studi
evalu
use
hcv
diseas
also
initi
upregul
activ
cell
inhibit
cell
activ
reduc
product
arrest
cell
cycl
progress
also
shown
impact
cell
respons
anim
tumor
model
human
human
trial
use
block
mab
demonstr
reduct
tumor
mass
clinic
benefit
substanti
minor
treat
subject
studi
role
chronic
infect
produc
mix
result
chronic
hiv
infect
mani
studi
indic
impair
cell
function
associ
viral
persist
although
function
caus
hiv
persist
suppress
cell
function
remain
unclear
hand
role
chronic
hcv
infect
seem
defin
hcvspecif
cell
found
liver
chronic
hcv
patient
overexpress
also
coexpress
observ
liverinfiltr
lymphocyt
peripher
blood
lymphocyt
suggest
phenotyp
differ
virusspecif
cell
differ
vivo
compart
express
hcvspecif
cell
profoundli
dysfunct
tremelimumab
fulli
human
mab
direct
phase
ii
studi
hiv
diseas
drug
withdrawn
prior
enrol
clinic
trial
hcv
diseas
still
underway
tremelimumab
bind
activ
lymphocyt
result
inhibit
downregul
tcell
activ
also
act
stimul
gener
use
xenomous
technolog
figur
anticanc
agent
current
worldwid
phase
iii
develop
malign
melanoma
phase
ii
develop
colorect
cancer
gastrointestin
cancer
gynecolog
cancer
nonsmal
cell
lung
cancer
us
countri
also
investig
prostat
breast
pancreat
cancer
variou
countri
antibodi
immunerel
advers
effect
tremelimumab
special
interest
presum
mechan
action
experi
identifi
manag
treatmentrel
side
effect
deriv
studi
cancer
particularli
melanoma
effect
mainli
includ
colitisdiarrhea
dermat
hepat
endocrinopathi
uveiti
nephriti
inflammatori
myopathi
also
occasion
report
uniqu
side
effect
like
direct
result
break
immun
toler
upon
blockad
gener
mild
revers
manag
follow
specif
treatment
guidelin
includ
symptomat
therapi
system
corticosteroid
decemb
pfizer
initi
phase
ii
trial
patient
latestag
unresect
liver
cancer
also
hepat
c
infect
primari
endpoint
singlearm
studi
abil
tremelimumab
produc
tumor
respons
among
hcvinfect
patient
hepatocellular
carcinoma
produc
chang
hepat
c
viral
load
first
result
indic
tremelimumab
demonstr
excel
safeti
profil
promis
antitumor
efficaci
hcc
patient
well
intens
antivir
activ
fact
signific
progress
declin
serum
hcv
viral
load
observ
associ
increas
antihcv
immun
respons
patient
sinc
multipl
level
immunoregul
synergist
use
antibodi
differ
checkpoint
molecul
might
repres
next
stage
immunotherapi
chronic
infecti
diseas
evidenc
ex
vivo
studi
combin
blockad
hcv
diseas
furthermor
host
mechan
inhibit
cell
activ
common
conserv
asid
specif
virusencod
immun
evas
strategi
antibodi
target
inhibitori
receptor
may
prove
extrem
versatil
drug
potenti
effect
multipl
class
virus
need
treat
hiv
hcv
infecti
diseas
two
epidem
global
impact
reawaken
interest
mabbas
therapi
support
varieti
clinic
studi
result
emerg
help
creat
model
develop
drug
extend
use
virus
well
although
mab
product
cost
high
increas
advanc
biotechnolog
product
system
make
competit
market
new
approach
use
mab
cocktail
combin
mab
avail
drug
improv
effect
treatment
mab
part
drug
regimen
like
futur
mab
block
hcv
hiv
infect
order
avoid
viral
escap
chronic
treatment
could
attract
invest
pharmaceut
compani
furthermor
broad
spectrum
mab
bavituximab
immunomodulatori
mab
could
use
whole
rang
diseas
thu
extend
market
profit
margin
review
focus
use
intact
mab
novel
emerg
versatil
class
pharmaceut
import
note
howev
biotechnolog
also
provid
opportun
build
variou
antibodi
format
whose
improv
pharmacokinet
pharmacodynam
properti
could
coopt
fight
infecti
diseas
adcc
antibodydepend
cellmedi
cytotox
cdc
complementdepend
cytotox
chocel
chines
hamster
ovari
cell
cmv
cytomegaloviru
cr
cytokinereleas
syndrom
cytotox
lymphocyt
antigen
fab
fragment
antigenbind
fc
fragment
crystalliz
receptor
fc
segment
iga
receptor
fc
segment
igg
gitr
glucocorticoidinduc
tnf
receptor
hav
hepat
viru
hbv
hepat
b
viru
hcv
hepat
c
viru
hiv
human
immunodefici
viru
ifn
interferon
ig
immunoglobulin
il
interleukin
iv
intraven
lymphocyt
activ
gene
lcmv
lymphocyt
choriomening
viru
lvp
lipoviralparticl
mab
monoclon
antibodi
mhc
major
histocompat
complex
nab
neutral
antibodi
nk
natur
killer
cell
program
cell
death
ps
phosphatidylserin
virus
use
coreceptor
rsv
respiratori
syncyti
viru
sc
subcutan
tcr
cell
antigen
receptor
tem
cell
effector
memori
cell
transform
growth
factor
mucin
domain
protein
tnf
tumor
necrosi
factor
treg
cell
immunosuppress
regulatori
cell
vzv
vesicular
stomat
viru
virus
use
coreceptor
author
declar
compet
interest
mc
author
patent
mab
pglycoprotein
patent
number
mab
suitabl
clinic
applic
hiv
andor
hcv
diseas
mf
aa
contribut
equal
write
edit
manuscript
mc
sv
critic
review
manuscript
made
final
chang
author
read
approv
final
version
manuscript
mf
doctor
immunolog
univers
rome
tor
vergata
itali
enrol
research
depart
therapeut
research
medicin
evalu
istituto
superior
di
rome
itali
iss
acquir
extens
expertis
biotechnolog
isol
character
genet
manipul
human
mab
singl
chain
format
develop
biolog
construct
design
clinic
use
aa
sinc
doctor
genet
molecular
biolog
univers
rome
la
sapienza
itali
enrol
research
depart
therapeut
research
medicin
evalu
iss
develop
extens
skill
biotechnolog
strategi
genet
manipul
recombin
antibodi
order
design
construct
suitabl
clinic
applic
mc
sinc
director
section
pharmacogenet
drug
resist
experiment
therapeut
depart
therapeut
research
medicin
evalu
iss
expert
member
emea
pharmaeuropa
iss
evalu
biotech
deriv
product
gmp
inspect
research
activ
mainli
aim
elucid
complex
phenomenon
multidrug
resist
mdr
identif
specif
mab
sv
current
director
depart
therapeut
research
medicin
evalu
iss
main
research
interest
dr
vella
follow
develop
antiretrovir
therapi
studi
hiv
resist
antiretrovir
drug
mechan
immun
reconstitut
final
oper
implement
research
resourc
limit
set
chair
particip
mani
intern
clinic
studi
antiretrovir
therapi
current
coordin
european
commissionfund
hiv
clinic
trial
network
neat
prepubl
histori
paper
access
http
